Navigation Links
Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
Date:6/28/2013

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In their report being published online in the Journal of the National Cancer Institute, Massachusetts General Hospital (MGH) Cancer Center investigators describe finding that the HOXB13/IL17BR ratio can indicate which women are at risk for cancer recurrence after tamoxifen and which are most likely to benefit from continuing treatment with the aromatase inhibitor letrozole (Femara).

"Most patients with early-stage, ER-positive breast cancer remain cancer-free after five years of tamoxifen treatment, but they remain at risk of recurrence for 15 years or longer after their initial treatment," says Dennis Sgroi, MD, of the MGH Cancer Center and Department of Pathology, lead and corresponding author of the report. "Our biomarker identifies the subgroup of patients who continue to be at risk of recurrence after tamoxifen treatment and who will benefit from extended therapy with letrozole, which should allow many women to avoid unnecessary extended treatment."

Previous research by Sgroi's team, in collaboration with investigators from bioTheranostics Inc., discovered that the ratio between levels of expression of two genes HOXB13 and IL17BR in tumor tissue predicted the risk of recurrence of ER-positive, lymph-node-negative breast cancer, whether or not the patient was treated with tamoxifen. The current study of patients from MA.17, the highly successful clinical trial of letrozole, was designed to evaluate the usefulness of the HOXB13/IL17BR ratio for both prognosis predicting which tamoxifen-treated remained patients at risk of recurrence and for identifying who could benefit from continued treatment with letrozole.

To answer those questions the investigators analyzed prim
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New concussion data: 2 biomarkers better than 1
2. MET protein levels show promise as biomarker for aggressive colon cancer
3. Researchers narrow the search for biomarkers of drug resistance in head and neck cancer patients
4. Kantar Health Launches CancerMPact Biomarker Analysis
5. Biomarkers discovered for inflammatory bowel disease
6. Leading researchers report on the elusive search for biomarkers in Huntingtons disease
7. The search for an early biomarker to fight atherosclerosis
8. VEGF may not be relevant biomarker for advanced prostate cancer
9. Possible predictive biomarker for patients who may respond to autophagy inhibitors
10. Office workers carry biomarker of potentially harmful flame retardant, study finds
11. Trio of biomarkers may help identify kidney cancer in early stages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 2015 , ... RxNT , an innovative software solutions ... cloud-based mobile ePrescribing application. The release of this enhanced iPhone app marks the ... in health technology, RxNT was one of the first to build an ePrescribing ...
(Date:9/2/2015)... Schwerzenbach, Switzerland (PRWEB) , ... September 02, 2015 ... ... quality control of incoming goods, intermediate or final products. Automating sample handling makes ... and automated sample handling, showing each step of the automated workflow and the ...
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC ... has earned international recognition as a premier center for treatment of and research ... catastrophic internal bleeding and stroke. , Cure HHT, previously known as The ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and educator ... and Associate Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) ... CDI Boot Camps. She serves as a CDI subject matter expert for a variety ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China ... international investment and business conference will be hosted at five star Beijing Kunlun ... full-weekend networking conference will feature leading EB-5 industry professionals and Chinese private equity ...
Breaking Medicine News(10 mins):Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2
... Inc. (Nasdaq: MYL ) today announced that ... its delisting offer for the publicly held shares of ... ingredient manufacturer in which Mylan acquired a controlling interest ... rupees per share, which was established by the reverse ...
... George Tiller is an abhorrent act of violence, and his ... moment. Federal law enforcement is coordinating with local law ... and I have directed the United States Marshals Service to ... nation. The Department of Justice will work to bring ...
... (May 31, 2009)Fox Chase Cancer Center investigators report that ... metastatic kidney cancer in a phase I trial. Early ... may be active in patients with rare forms of ... to other targeted therapies. , Elizabeth Plimack, M.D., M.S., ...
... MAY 31, 2009 The American Society for ... of endoscopy during the fifth annual ASGE Crystal Awards on ... this year,s event will begin at 6:30 p.m. at Navy ... Disease Week (DDW), the ASGE Crystal Awards symbolize the finest ...
... to start San Francisco-to-Los Angeles ride May 31SAN FRANCISCO ... bicyclists from 41 states and 14 nations will stream ... to Los Angeles as participants in the colorful and ... trek is expected to raise $10.5 million to support ...
... PITTSBURGH, May 30 Patients undergoing treatment for advanced ... addition of gefinitib to chemotherapy, according to a study ... by Ethan Argiris, M.D., associate professor of medicine, University ... Head and Neck Cancer Program of the University of ...
Cached Medicine News:Health News:Mylan Announces Successful Matrix Delisting Offer 2Health News:2-drug combination appears safe and active in metastatic kidney cancer 2Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 2Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 3Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 4Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 5Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 6Health News:ASGE and ASGE Foundation hold Crystal Awards Dinner as part of Digestive Disease Week 7Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 3Health News:AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS 4Health News:New treatment combination proves safe for head and neck cancer patients 2
(Date:9/2/2015)... , Sept. 2, 2015 About Duchenne ... X-linked disease, which generally affects the male population. ... weakness. The disease is caused due to mutations ... lack of production of dystrophin (a protein essential ... lack of dystrophin weakens muscle function, causes loss ...
(Date:9/2/2015)... 2015 About Chronic Lymphocytic Leukemia ... by increased production of lymphocytes. It has been observed ... can spread to other parts of the body. This ... the slow buildup of the cancerous cells. During the ... spleen, liver, and lymph nodes. The course of the ...
(Date:9/2/2015)... and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the addition of ... November 26-27, 2015)" conference to their offering. ... key areas of pharmaceutical regulatory affairs in China ... Macau and Taiwan and ... gaining and maintaining a successful Marketing Authorisation in the region ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... PARSIPPANY, N.J. , June 28 Preliminary ... with diabetes and hypertension demonstrated that the investigational triple ... (40/10/25 mg) resulted in a statistically significant greater Least ... at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm ...
... , June 28 Codexis, Inc. (Nasdaq: CDXS ... company as Senior Vice President, Commercial Operations, a new position.  Mr. ... operations worldwide.  He will report to Joseph Sarret , M.D., ... , , , ...
Cached Medicine Technology:New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 2New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 3New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 4New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 5New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 6New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 7Codexis Names Peter Strumph SVP, Commercial Operations 2
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Bio Vortex Adapter in conjunction with the Vortex ... Using the Mo Bio Vortex Adapter is an ... Prep machines which offer the same technology. ... tubes at one time and will fit any ...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Compact Housing Model V-500 ... to handle most vacuum applications. Applications ... two rotary evaporators Laboratory vacuum source ...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Model V-500 is a powerful ... vacuum applications. Applications Ideally suited ... Laboratory vacuum source for instruments including ...
Medicine Products: